



15 MAR 2006 PCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor: Nattel, Stanley

Int. Application: PCT/CA 2004/000911

Filed: 06/18/2003

Title: Preventing atrial fibrillation (af) with
the use of statin drugs.

Attorney Docket No.: 20111-43

Group Art Unit: Unknown

Examiner: To be assigned

Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

This Information Disclosure Statement is submitted:

☐ under 37 CFR 1.97(b), or
(Within three months of filing national application; or date of entry of international application; or before mailing date of first office action on the merits; whichever occurs last)

☒ under 37 CFR 1.97(c) together with either a:

☒ Statement under 37 CFR 1.97(e):

The Applicant respectfully submits that each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement, or

☐ a \$180.00 fee under 37 CFR 1.17(p), or
(After the CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)

☐ under 37 CFR 1.97(d) together with a:

☐ Statement under 37 CFR 1.97(e), and

☐ a \$180.00 fee set forth in 37 CFR 1.17(p).


(Filed after final action or notice of allowance, whichever occurs first, but before payment of the issue fee)

X Applicant(s) submit herewith Form PTO/SB/08B -Information Disclosure Statement by Applicant together with copies, of patents, publications or other information of which applicant(s) are aware, which applicant(s) believe(s) may be material to the examination of this application and for which there may be a duty to disclose in accordance with 37 CFR 1.56.

The relevance of the attached references is that this is the closest art of which Applicant is aware.

It is requested that the information disclosed herein be made of record in this application.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'Louis Tessier', is written over a horizontal line.

Louis Tessier
Agent for Applicant(s)
Reg. No 45,289

Date: March 9, 2006

Telephone No.: (514) 990-3434

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	PCT/CA 2004/000911
		Filing Date	06/18/2003
		First Named Inventor	NATTEL, Stanley
		Art Unit	
		Examiner Name	
Sheet 1	of 4	Attorney Docket Number	20111-43

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		DRESING TJ, ET AL. ATRIAL FIBRILLATION. THE CLEVELAND CLINIC, DEPART. OF CARDIOVASCULAR MEDICINE, MAY 30, 2002, WWW.CLEVELANDCLINICMEDED.COM	
		WIJFFELS MC ET AL. ATRIAL FIBRILLATION BEGETS ATRIAL... CIRCULATION OCTOBER 1995 PP.1954-1968 VOL. 92 No.7 US	
		MORILLO CARLOS A. ET AL. CHRONIC RAPID ATRIAL PACING. CIRCULATION, MARCH 1995 PP. 1588-1595 CA	
		ELVAN ARIF ET AL. PACING-INDUCED CHRONIC ATRIAL FIBRILLATION... CIRCULATION. DECEMBER 1996 PP. 2953-2960 VOL. 94 NO. 11 US	
		GASPO RANIA ET AL. FUNCTIONAL MECHANISMS UNDERLYING TACHYCARDIA-INDUCED... CIRCULATION DECEMBER 1997 PP. 4027-4035 VOL. 96 NO.11 CA	
		NATTEL STANLEY. THERAPEUTIC IMPLICATIONS OF ATRIAL FIBRILLATION... CARDIOVASCULAR RESEARCH, MAI 2002 PP.347-360 VOL. 54 CA	
		SAMIR FAREH ET AL. THE T-TYPE CA ²⁺ CHANNEL BLOCKER ... CIRCULATION, NOVEMBER 1999 PP. 2191-2197 VOL. 100 CA	
		SAMIR FAREH ET AL. DIFFERENTIAL EFFICACY OF L-AND T-TYPE... CARDIOVASCULAR RESEARCH, MARCH 2001 PP.762-770 VOL. 49 CA	
		SHINAGAWA KAORI ET AL. EFFECTS OF ANTIARRHYTHMIC DRUGS... CIRCULATION, MARCH 2003 PP.1440-1446 CA	
		MIHM MICHAEL J. IMPAIRED MYOFIBRILLAR ENERGETICS AND OXIDATIVE... CIRCULATION, JULY 2001 PP.174-180 VOL. 104 US	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	PCT/CA 2004/000911
		Filing Date	06/18/2003
		First Named Inventor	NATTEL, Stanley
		Art Unit	
		Examiner Name	
Sheet	2	of	4
		Attorney Docket Number	20111-43

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		CARNES CYNTHIA A. ET AL. ASCORBATE ATTENUATES ATRIAL PACING-INDUCED... CIRCULATION, SEPTEMBER 2001 PP.E32.E38 VOL. 89 US	
		CHUNG MINA K. ET AL. INFLAMMATORY MECHANISMS AND PERSISTENCE... CIRCULATION, DECEMBER 2001 PP.2886-2891 VOL. 104 US	
		RONNIER J. AVILES ET AL. INFLAMMATION AS A RISK... CIRCULATION, DECEMBER 2003 PP.3006-3010 VOL. 108 US	
		GABRIELE WEITZ-SCHMIDT. STATINS AS ANTI-INFLAMMATORY AGENTS. TRENDS IN PHARMOCOLOGICAL SCIENCES, OCTOBER 2002 PP. 482-487 VOL. 23 NO. 10 SWITZERLAND	
		SHISHEHBOR, MARIE-LUISE ET AL. STATINS PROMOTE POTENT SYSTEMIC. CIRCULATION, JULY 2003 PP.426-431 VOL. 108 US	
		SAMIR FAREH ET AL. IMPORTANCE OF REFRACTORINESS HETEROGENEITY IN THE ENHANCED... CIRCULATION, NOVEMBER 1998 PP. 2202-2209 VOL. 98 CA	
		LIXIA YUE ET AL. IONIC REMODELING UNDERLYING ACTION POTENTIAL... CIRCULATION RESEARCH, OCTOBER 1997 PP.512-525 VOL. 81 NO. 4 CA	
		LIXIA YUE ET AL. MOLECULAR MECHANISMS UNDERLYING IONIC REMODELING ... CIRCULATION RESEARCH, APRIL 1999 PP.776-784 CA	
		BIANCA J.J.M. BRUNDEL ET AL. ION CHANNEL REMODELING IS RELATED TO INTRAOPERATIVE ATRIAL... CIRCULATION, FEBRUARY 2001 PP.684-690 NETHERLANDS	
		BIANCA J.J.M. BRUNDEL ET AL. GENE EXPRESSION OF PROTEINS INFLUENCING THE CALCIUM ... CARDIOVASCULAR RESEARCH, MAY 1999 PP.443-454 VOL. 42 NETHERLANDS	

Examiner Signature	Date Considered
---------------------------	------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	PCT/CA 2004/000911
		Filing Date	06/18/2003
		First Named Inventor	NATTEL, Stanley
		Art Unit	
		Examiner Name	
Sheet	3	of	4
		Attorney Docket Number	20111-43

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		ANDREAS GOETTE ET AL. ELECTRICAL REMODELING IN ATRIAL FIBRILLATION. CIRCULATION, DECEMBER 1996 PP.2968-2974 VOL. 94 NO. 11 GA	
		ELISABETH LEISTAD ET AL. ATRIAL CONTRACTILE DYSFUNCTION AFTER SHORT-TERM... CIRCULATION, MAY 1996 PP.1747-1754 VOL. 93 NO. 9 OSLO, NORWAY	
		EMILE G. DAOUD ET AL. EFFECT OF VERAPAMIL AND PROCAINAMIDE ON ATRIAL... CIRCULATION, SEPTEMBER 1997 PP. 1542-1550 VOL. 96 NO. 5 MI	
		WEN-CHUNG YU ET AL. TACHYCARDIA-INDUCED CHANGE OF ATRIAL... CIRCULATION, JUNE 1998 PP. 2331-2337 VOL. 97 TAIWAN	
		SHIH-HUANG LEE ET AL. EFFECT OF VERAPAMIL ON LONG-TERM TACHYCARDIA-INDUCED ATRIAL... CIRCULATION, JANUARY 2000 PP.200-206 VOL. 101 TAIWAN	
		J. VIJAY JAYACHANDRAN ET AL. ROLE OF THE NA ⁺ /H ⁺ EXCHANGER IN SHORT-TERM... CIRCULATION, APRIL 2000 PP.1861-1866 VOL.101 IN.	
		HIDEKO NAKASHIMA ET AL. ANGIOTENSIN II ANTOGONIST PREVENTS ELECTRICAL ... CIRCULATION, JUNE 2000 PP.2612-2617 VOL. 101 JAPAN	
		KAORI SHINAGAWA ET AL. EFFECTS OF INHIBITING NA ⁺ /H ⁺ EXCHANGE OR ANGIOTENSIN... CARDIOVASCULAR RESEARCH, MAY 2002 PP.438-446 VOL. 54 CA	
		MASAO TAKEMOTO ET AL. STATINS AS ANTIOXIDANT THERAPY FOR PREVENTING CARDIAC... THE JOURNAL OF CLINICAL INVESTIGATION, NOVEMBER 2001 PP. 1429-1437 VOL. 108 NO. 10 US	
		ULRICH LAUFS ET AL. UPREGULATION OF ENDOTHELIAL NITRIC OXIDE... CIRCULATION, MARCH 1998 PP. 1129-1135 VOL. 97 US	

Examiner Signature	Date Considered
---------------------------	------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	PCT/CA 2004/000911
		Filing Date	06/18/2003
		First Named Inventor	NATTEL, Stanley
		Art Unit	
		Examiner Name	
Sheet 4	of 4	Attorney Docket Number	20111-43

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		YASUKO KUREISHI ET AL. THE HMG-COA REDUCTASE INHIBITOR SIMVASTATIN... NATURE MEDECINE, SEPTEMBER 2000 PP. 1004-1010 VOL. 6 NO. 8 US	
		LUO JIAN DONG ET AL. EFFECTS OF SIMVASTATIN ON ACTIVITIES OF ENDOGENOUS ANTIOXIDANT... ACTA PHARMACOL, FEBRUARY 2002, PP.124-128 CHINA	
		BALZ FREI ET AL. ASCORBATE IS AN OUTSTANDING ANTIOXIDANT IN HUMAN BLOOD PLASMA. MEDICAL SCIENCE, AUGUST 1989, PP. 6377-6381, VOL. 86 US	
		MAREYUKI TAKAHASHI ET AL. SCAVENGING OF RADIALS BY VITAMIN E IN THE MEMBRANES... J. AM. CHEM. SOC., AUGUST 1989 PP. 6350-6353 VOL. 111 JAPAN	
		HUA CAI ET AL. DOWNREGULATION OF ENDOCARDIAL NITRIC OXIDE SYNTHASE... CIRCULATION, NOVEMBER 2002 PP. 2854-2858 GA	
		KUMI SATOH ET AL. EFFECTS OF 3-HYDROXY-3- METHYLGLUTARYL COENZYME ... BRITISH JOURNAL OF PHARMACOLOGY. SEPTEMBER 1995 PP. 1894-1898 VOL. 116 JAPAN	
		SEEMA MITAL ET AL. SIMVASTATIN UPREGULATES CORONARY VASCULAR ENDOTHELIAL... AM J. PHYSIOL HEART CIRC., DECEMBER 2000 PP. H2649-H2657 VOL. 279 US	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.